Innovation For Life

Defeating Pain, Controlling Inflammation

Our Company
We are a pre-clinical stage pharmaceutical company using our proprietary NCE to treat acute and chronic inflammation. We will offer our products for licensing post Ph II studies in high unmet need indications.

Our Science

Our NCE target the endocannabinoid and cyclooxygenase pathways. Our technology allows intravenous, topical and intranasal delivery.

Our Indications

Our NCE will benefit patients suffering the pain and inflammation of dry eye syndrome, and those experiencing pain after surgery.

CONTACT US

Phone: 514 883 3447

Email: info@tallcinc.com

NEWS

TALLC Corporation Announces Grant of New SmartCelle Patent for
Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

https://lnkd.in/d7mAUJy https://lnkd.in/dutC_T9

The role of Cannabinoid receptors on light-induced photoreceptor degeneration | IOVS | ARVO Journals https://iovs.arvojournals.org/article.aspx?articleid=2149928#.X0_PeHxV7DY.twitter

Santen and NTC announce results of phase III LEADER-7 study https://buff.ly/3ewnVS9

Load More...

© TALLC Inc. 2020